Blog

Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results Lead to Early Trial Halt for Success

EBR Systems

Posted on

August 22, 2024

Excellent interim analysis results lead to early trial success and are a major company milestone, significantly de-risks EBR Systems.

July 31, 2024

EBR's pivotal SOLVE-CRT Study published in JAMA Cardiology

JAMA Cardiology publishes EBR’s pivotal SOLVE-CRT study

July 30, 2024

ASX Quarterly Health Wrap: Who is making progress for FDA approval?

Australian Business Review article of EBR Systems progress in 2024

February 6, 2024

How big-hearted EBR Systems is pacing a multi-billion dollar cardiac market

EBR Systems pioneered the WiSE Cardiac Resynchronization Therapy (CRT) system tech, the size of a grain of rice.

May 22, 2023

‘Next Cochlear’ stock surges after heart device breakthrough

Shares in an ASX-listed medical technology firm backed by investors including Bill Ferris and Mark Carnegie have surged 10.5 per cent on Monday after it revealed positive clinical trial results, which clear the way for US Food and Drug Administration approval for its tiny cardiovascular device.

November 23, 2021

'Big unmet need' for smallest heart device

EBR Systems makes a tiny gadget that sits inside the heart to help it pump enough blood, and is working towards regulatory approval in Australia and the US.

November 20, 2021

'World-first': How a tiny, rice-sized device transformed a woman's life

Jeffrey Alison and a device the size of a small grain of rice have transformed Ms Neu's life.

November 15, 2021

NCH testing a cutting-edge miniature pacemaker no bigger than a grain of rice

Keeping pace with technology, NCH is launching a research institute to test and deliver the latest medical advances. One of which is a new, and small, heart pacemaker.